MicroRNAs in breast cancer therapy

Current Pharmaceutical Design

Volumn 20, Issue 33, 2014, Pages 5268-5274

  Tang, Joy ^a   Ahmad, Aamir ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer therapy; Diagnostic biomarkers; microRNAs (miRNAs); Prognostic biomarkers

Indexed keywords

ANTINEOPLASTIC AGENT; MICRORNA; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER GENE THERAPY; CANCER PROGNOSIS; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; GENE DELIVERY SYSTEM; GENE TARGETING; HUMAN; MOLECULAR DIAGNOSIS; NONHUMAN; PRIORITY JOURNAL; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; GENETICS; METABOLISM; PATHOLOGY; TUMOR EMBOLISM;

BREAST NEOPLASMS; FEMALE; HUMANS; MICRORNAS; NEOPLASTIC CELLS, CIRCULATING;

EID: 84915800973     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140128205239     Document Type: Article

References (89)

1. Ahmad A, Ali AS, Ali S, et al. MicroRNAs: Targets of Interest in Breast Cancer Research. In: Mulligan JA, Ed. MicroRNA: Expression, Detection and Therapeutic Strategies Hauppauge: Nova Science Publishers, Inc. 2011. pp. 59-78.
2. Pillai RS, Bhattacharyya SN, Filipowicz W. Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol 2007; 17: 118-26.
3. Iorio MV, Casalini P, Piovan C, et al. Breast cancer and microRNAs: therapeutic impact. Breast 2011; 20 Suppl 3: S63-70.
4. Lagos-Quintana M, Rauhut R, Yalcin A, et al. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002; 12: 735-9.
5. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007; 318: 1931-4.
6. O'Day E, Lal A. MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res 2010; 12: 201.
7. Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev 2009; 28: 369-78.
8. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-33.
9. Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell 2005; 122: 6-7.
10. Valastyan S, Weinberg RA. MicroRNAs: Crucial multi-tasking components in the complex circuitry of tumor metastasis. Cell cycle 2009; 8: 3506-12.
11. Barcenas CH, Wells J, Chong D, et al. Race as an independent risk factor for breast cancer survival: breast cancer outcomes from the medical college of georgia tumor registry. Clin Breast Cancer 2010; 10: 59-63.
12. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO 2012; 4: 143-59.
13. Hassan O, Ahmad A, Sethi S, et al. Recent updates on the role of microRNAs in prostate cancer. J Hematol Oncol 2012; 5: 9.
14. Kong YW, Ferland-McCollough D, Jackson TJ, et al. microRNAs in cancer management. Lancet Oncol 2012; 13: e249-58.
15. Fabian MR, Sonenberg N. The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC. Nat Struc Mol Biol 2012; 19: 586-93.
16. Ahmed A, Ali AS, Ali S, et al. MicroRNAs in breast cancer research: progress and promise. In: Ahmad A, Ed. Breast Cancer Metastasis and Drug Resistance. New York: Springer 2012. pp. 399-413.
17. Foekens JA, Sieuwerts AM, Smid M, et al. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci USA 2008; 105: 13021-6.
18. Zhou X, Marian C, Makambi KH, et al. MicroRNA-9 as potential biomarker for breast cancer local recurrence and tumor estrogen receptor status. PLoS One 2012; 7: e39011.
19. Gaur A, Jewell DA, Liang Y, et al. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 2007; 67: 2456-68.
20. Nicoloso MS, Spizzo R, Shimizu M, et al. MicroRNAs-the micro steering wheel of tumour metastases. Nat Rev Cancer 2009; 9: 293-302.
21. Adams BD, Guttilla IK, White BA. Involvement of microRNAs in breast cancer. Semin Reprod Med 2008; 26: 522-36.
22. Tang J, Ahmad A, Sarkar FH. The Role of MicroRNAs in Breast Cancer Migration, Invasion and Metastasis. Int J Mol Sci 2012; 13: 13414-37.
23. Barry M, Kell MR. Enhancing the adjuvant treatment of hormone receptor positive breast cancer. Breast J 2009; 15: 194-8.
24. Lowery AJ, Miller N, McNeill RE, et al. MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management. Clin Cancer Res 2008; 14: 360-5.
25. Chin LJ, Slack FJ. A truth serum for cancer-microRNAs have major potential as cancer biomarkers. Cell Res 2008; 18: 983-4.
26. Krell J, Frampton AE, Jacob J, et al. miRNAs in breast cancer: ready for real time? Pharmacogenomics 2012; 13: 709-19.
27. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer cell 2006; 9: 189-98.
28. Fassan M, Sachsenmeir K, Rugge M, et al. Role of miRNA in distinguishing primary brain tumors from secondary tumors metastatic to the brain. Front Biosci 2011; 3: 970-9.
29. Roldo C, Missiaglia E, Hagan JP, et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2006; 24: 4677-84.
30. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65: 7065-70.
31. Stinson S, Lackner MR, Adai AT, et al. TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer. Sci Signal 2011; 4: ra41.
32. Stinson S, Lackner MR, Adai AT, et al. miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-tomesenchymal transition in breast cancer. Sci Signal 2011; 4: pt5.
33. Zhao R, Wu J, Jia W, et al. Plasma miR-221 as a predictive biomarker for chemoresistance in breast cancer patients who previously received neoadjuvant chemotherapy. Onkologie 2011; 34: 675-80.
34. Rao X, Di Leva G, Li M, et al. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 2011; 30: 1082-97.
35. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006.
36. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-61.
37. Roth C, Rack B, Muller V, et al. Circulating microRNAs as bloodbased markers for patients with primary and metastatic breast cancer. Breast Cancer Res 2010; 12: R90.
38. Heneghan HM, Miller N, Kerin MJ. Circulating microRNAs: promising breast cancer Biomarkers. Breast Cancer Res 2011; 13: 402; author reply 3.
39. Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. PLoS One 2008; 3: e3148.
40. Zhao H, Shen J, Medico L, et al. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One 2010; 5: e13735.
41. Mostert B, Sieuwerts AM, Martens JW, et al. Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer patients. Expert review of molecular diagnostics 2011; 11: 259-75.
42. Heneghan HM, Miller N, Lowery AJ, et al. MicroRNAs as Novel Biomarkers for Breast Cancer. Journal of oncology 2009; 2009: 950201.
43. Taplin S, Abraham L, Barlow WE, et al. Mammography facility characteristics associated with interpretive accuracy of screening mammography. J Natl Cancer Inst 2008; 100: 876-87.
44. Thompson A, Brennan K, Cox A, et al. Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. Breast Cancer Res 2008; 10: R26.
45. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New Engl J Med 2005; 353: 1659-72.
46. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-8.
47. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524-9.
48. Xi Y, Nakajima G, Gavin E, et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 2007; 13: 1668-74.
49. Li J, Smyth P, Flavin R, et al. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotech 2007; 7: 36.
50. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-8.
51. Yu SL, Chen HY, Chang GC, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer cell 2008; 13: 48-57.
52. Schetter AJ, Nguyen GH, Bowman ED, et al. Association of inflammation-related and microRNA gene expression with cancerspecific mortality of colon adenocarcinoma. Clin Cancer Res 2009; 15: 5878-87.
53. Ji J, Shi J, Budhu A, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009; 361: 1437-47.
54. Ma L, Young J, Prabhala H, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nature Cell Biol 2010; 12: 247-56.
55. Valastyan S, Reinhardt F, Benaich N, et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 2009; 137: 1032-46.
56. Rothe F, Ignatiadis M, Chaboteaux C, et al. Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS One 2011; 6: e20980.
57. Camps C, Buffa FM, Colella S, et al. hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Research 2008; 14: 1340-8.
58. Ahmad A. Pathways to breast cancer recurrence. ISRN Oncol 2013; 2013: 290568.
59. Kong KL, Kwong DL, Chan TH, et al. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut 2012; 61: 33-42.
60. Khew-Goodall Y, Goodall GJ. Myc-modulated miR-9 makes more metastases. Nature Cell Biology 2010; 12: 209-11.
61. Tan HX, Wang Q, Chen LZ, et al. MicroRNA-9 reduces cell invasion and E-cadherin secretion in SK-Hep-1 cell. Med Oncol 2010; 27: 654-60.
62. Calin GA, Cimmino A, Fabbri M, et al. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci USA 2008; 105: 5166-71.
63. Si ML, Zhu S, Wu H, et al. miR-21-mediated tumor growth. Oncogene 2007; 26: 2799-803.
64. Iorio MV, Casalini P, Piovan C, et al. microRNA-205 regulates HER3 in human breast cancer. Cancer Res 2009; 69: 2195-200.
65. Saito Y, Liang G, Egger G, et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer cell 2006; 9: 435-43.
66. Zoghi B, Chang YF, Subbarayalu P, et al. miRNAs as novel therapeutic adjuvants for the prognosis and treatment of triple negative breast cancers. J Cancer Res 2012; 72.
67. Imam JS, Buddavarapu K, Lee-Chang JS, et al. MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers. Oncogene 2010; 29: 4971-9.
68. Yeung ML, Jeang KT. MicroRNAs and cancer therapeutics. Pharm Res 2011; 28: 3043-9.
69. De Paula D, Bentley MV, Mahato RI. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA 2007; 13: 431-56.
70. Pichiorri F, Palmieri D, De Luca L, et al. In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. J Exp Med 2013; 210: 951-68.
71. Bader AG, Brown D, Stoudemire J, et al. Developing therapeutic microRNAs for cancer. Gene Tther 2011; 18: 1121-6.
72. Nana-Sinkam SP, Croce CM. MicroRNAs as therapeutic targets in cancer. Transl Res 2011; 157: 216-25.
73. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010; 9: 775-89.
74. Weiler J, Hunziker J, Hall J. Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? Gene Ther 2006; 13: 496-502.
75. Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438: 685-9.
76. Meister G, Landthaler M, Dorsett Y, et al. Sequence-specific inhibition of microRNA-and siRNA-induced RNA silencing. RNA 2004; 10: 544-50.
77. Hutvagner G, Simard MJ, Mello CC, et al. Sequence-specific inhibition of small RNA function. PLoS biology 2004; 2: E98.
78. Ahmad A, Aboukameel A, Kong D, et al. Phosphoglucose isomerase/autocrine motility factor mediates epithelialmesenchymal transition regulated by miR-200 in breast cancer cells. Cancer Res 2011; 71: 3400-9.
79. Elmen J, Lindow M, Schutz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008; 452: 896-9.
80. Ebert MS, Sharp PA. MicroRNA sponges: progress and possibilities. RNA 2010; 16: 2043-50.
81. Gentner B, Schira G, Giustacchini A, et al. Stable knockdown of microRNA in vivo by lentiviral vectors. Nature Methods 2009; 6: 63-6.
82. Zhang S, Chen L, Jung EJ, et al. Targeting microRNAs with small molecules: from dream to reality. Clin Pharmacol Ther 2010; 87: 754-8.
83. Davis ME, Zuckerman JE, Choi CH, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010; 464: 1067-70.
84. Kota J, Chivukula RR, O'Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009; 137: 1005-17.
85. Davidson BL, McCray PB, Jr. Current prospects for RNA interference-based therapies. Nat Rev Gen 2011; 12: 329-40.
86. Gandellini P, Profumo V, Folini M, et al. MicroRNAs as new therapeutic targets and tools in cancer. Expert Opin Ther Targets 2011; 15: 265-79.
87. Trang P, Medina PP, Wiggins JF, et al. Regression of murine lung tumors by the let-7 microRNA. Oncogene 2010; 29: 1580-7.
88. Allen KE, Weiss GJ. Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics. Mol Cancer Ther 2010; 9: 3126-36.
89. Kong W, He L, Coppola M, et al. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem 2010; 285: 17869-79.